Seres Therapeutics (NASDAQ:MCRB) PT Lowered to $10.00 at Chardan Capital

Seres Therapeutics (NASDAQ:MCRB – Get Rating) had its target price cut by research analysts at Chardan Capital from $12.00 to $10.00 in a note issued to investors on Friday, The Fly reports. Chardan Capital’s target price indicates a potential upside of 87.97% from the company’s previous close. MCRB has been the subject of several other […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Davida Berry ,Noubarb Afeyan , ,Seres Therapeutics Inc ,Macroview Investment Management ,Jpmorgan Chase Co ,Life Insurance Co ,Great West Life Assurance Co ,Canaccord Genuity Group ,Bridgefront Capital ,Seres Therapeutics ,Get Rating ,Chardan Capital ,Genuity Group ,West Life Assurance ,Investment Management ,Seres Therapeutics Daily ,Nasdaq Mcrb ,Mcrb ,Medical ,Lower Price Target ,